Literature DB >> 25910471

Diastolic dysfunction in controlled hypertensive patients with mild-moderate obstructive sleep apnea.

Elisabetta Lisi1, Andrea Faini2, Grzegorz Bilo3, Laura Maria Lonati3, Miriam Revera3, Sabrina Salerno3, Valentina Giuli1, Carolina Lombardi4, Gianfranco Parati5.   

Abstract

BACKGROUND: Hypertension and severe obstructive sleep apnea (OSA) may independently contribute to left ventricular diastolic dysfunction. However, scanty data is available on this issue in hypertensives with mild-moderate OSA. METHODS AND
RESULTS: We performed polysomnography, echocardiography and 24h ambulatory blood pressure monitoring in 115 treated essential hypertensives with suspicion of OSA. After exclusion of severe/treated OSA and/or cardiovascular disease patients, mild-moderate OSA (5 ≤ apnoea/hypopnoea index<30 events·h(-1)) was diagnosed in 47.3% of the remaining 91 patients, while 52.7% were free of OSA. Transmitral early (E) and late (A) peak flow velocities were assessed in 69 patients, and mitral annular velocity (E') in 53. Compared to non-OSA, mild-moderate OSA heart rate was higher (p=0.031) while E/A was lower (p<0.001) without differences in 24h mean systolic and diastolic blood pressures (125.36 ± 12.46/76.46 ± 6.97 vs 128.63 ± 11.50/77.70 ± 7.72 mmHg, respectively, NS). Patients with E'< 10 cm/s and E/A<0.8 showed a lower mean SpO2 than subjects with normal diastolic function (p=0.004; p<0.001). In a logistic regression model age, mean SpO2, daytime heart rate and nocturnal diastolic blood pressure fall were associated with altered relaxation pattern, independently from BMI and gender.
CONCLUSIONS: In controlled hypertensives mild-moderate OSA may be associated with early diastolic dysfunction, independently from age, gender and mean blood pressure and in the absence of concentric left ventricular hypertrophy. Moreover nocturnal hypoxia may be a key factor in determining early diastolic dysfunction, under the synergic effects of hypertension and mild-moderate OSA.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Hypertension; Left ventricular diastolic function; Obstructive sleep apnea

Mesh:

Year:  2015        PMID: 25910471     DOI: 10.1016/j.ijcard.2015.02.037

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  6 in total

1.  Sleep-Disordered Breathing and Cardiovascular Correlates in College Football Players.

Authors:  Jonathan H Kim; Casey Hollowed; Morgan Irwin-Weyant; Keyur Patel; Kareem Hosny; Hiroshi Aida; Zaina Gowani; Salman Sher; Patrick Gleason; James L Shoop; Angelo Galante; Craig Clark; Yi-An Ko; Arshed A Quyyumi; Nancy A Collop; Aaron L Baggish
Journal:  Am J Cardiol       Date:  2017-07-25       Impact factor: 2.778

Review 2.  Obstructive Ventilatory Disorder in Heart Failure-Caused by the Heart or the Lung?

Authors:  Sergio Caravita; Jean-Luc Vachiéry
Journal:  Curr Heart Fail Rep       Date:  2016-12

Review 3.  Targeting subclinical organ damage in obstructive sleep apnea: a narrative review.

Authors:  Cesare Cuspidi; Marijana Tadic; Elisa Gherbesi; Carla Sala; Guido Grassi
Journal:  J Hum Hypertens       Date:  2020-08-14       Impact factor: 3.012

4.  Subclinical Left Ventricular Dysfunction in Patients with Obstructive Sleep Apnea.

Authors:  Sait Demirkol; Cengiz Ozturk; Sevket Balta; Murat Unlu; Zekeriya Arslan
Journal:  Med Princ Pract       Date:  2015-12-01       Impact factor: 1.927

5.  Risk of Obstructive Sleep Apnea and Echocardiographic Parameters.

Authors:  Adson Renato Leite; Diana Maria Martinez; Maria Luiza Garcia-Rosa; Erica de Abreu Macedo; Antonio José Lagoeiro; Wolney de Andrade Martins; Delvo Vasques-Netto; Cárita Cunha Dos Santos
Journal:  Arq Bras Cardiol       Date:  2019-12       Impact factor: 2.000

6.  Screening of plasma exosomal lncRNAs to identify potential biomarkers for obstructive sleep apnea.

Authors:  Xunxun Chen; Hongbing Liu; Rong Huang; Ran Wei; Yuchuan Zhao; Taoping Li
Journal:  Ann Transl Med       Date:  2022-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.